GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2006

Micromet Nets $10M Milestone Payment from Serono

  • Micromet received a $10-million milestone payment from Serono having completed two Phase II trials with its cancer drug.  Adecatumumab (MT201) was evaluated as a single agent for the treatment of metastatic breast cancer and prostate cancer. It is a human Mab targeting tumor cells overexpressing the epithelial cell adhesion molecule.

    Micromet and Serono reported final data for the two Phase II in October. The compound originated at Micromet and is being developed in a collaboration between the companies.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »